FDA approves 1st drug for neurotrophic keratitis
The USFDA has approved Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea.

Neurotrophic keratitis is a degenerative disease resulting from a loss of corneal sensation. The loss of corneal sensation impairs corneal health causing progressive damage to the top layer of the cornea, including corneal thinning, ulceration, and perforation in severe cases. The prevalence of neurotrophic keratitis has been estimated to be less than five in 10,000 individuals.

The most common adverse reactions in patients taking Oxervate are eye pain, ocular hyperemia (enlarged blood vessels in the white of the eyes), eye inflammation and increased lacrimation.

Oxervate also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.

Read more here: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm618047.htm
Dr. G●●●●●●●●r MG and 1 others like this3 shares
Like
Comment
Share